Clinicians' Views on Management and Terminology for Papillary Thyroid Microcarcinoma: A Qualitative Study

Brooke Nickel, Juan Brito Campana, Alexandra Barratt, Susan Jordan, Ray Moynihan, Kirsten McCaffery

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: There is growing acceptance that the increase in thyroid cancer incidence is in part a result of overdiagnosis of small low-risk papillary microcarcinomas (PMCs) with indolent clinical course. Although surgery is the cornerstone treatment for patients with PMCs, recent management guidelines are shifting toward inclusion of more conservative treatments such as active surveillance. There is little evidence on clinicians' experience in managing PMC patients and their attitudes toward treatment options, including their willingness to accept a nonsurgical option. The aim of this study was to understand how clinicians perceive a diagnosis of PMC, potential changes to terminology, and the treatment options available to patients. Methods: This was a qualitative study using semi-structured interviews conducted between November 2015 and May 2016 with 22 clinicians (seven endocrinologists and 15 thyroid surgeons). Transcribed audio-recordings were thematically coded, and a framework method was used to analyze the data. Results: Across a sample of clinicians who manage thyroid cancer patients, awareness of overdiagnosis and overtreatment of PMC was common. However, there was little acceptance of active surveillance to manage these patients. Clinicians did not feel comfortable recommending this management approach, as they were worried about the risk of metastases, did not feel that evidence to support this approach was strong enough, and also believed that patients currently have a high preference for surgery. The majority of clinicians did not believe that changing the terminology of this diagnosis was a viable strategy to reduce patients' anxiety and their perceived preference for more aggressive treatments. However, most clinicians felt that thyroid nodules <1 cm should not be biopsied, which could help minimize the risk of overdiagnosis of PMC. Conclusions: This study, based on a non-representative sample of 22 clinicians, which remains an important limitation, provides revealing insight into clinicians' management preferences and decision making for small low-risk thyroid cancers at a time when management guidelines and practices are evolving. It suggests that clinicians may not be ready to accept nonsurgical options, or changes in terminology, until evidence to support these options and changes is stronger.

Original languageEnglish (US)
Pages (from-to)661-671
Number of pages11
JournalThyroid
Volume27
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Terminology
Thyroid Neoplasms
Time Management
Thyroid Nodule
Therapeutics
Papillary Thyroid Microcarcinoma
Practice Guidelines
Decision Making
Thyroid Gland
Anxiety
Guidelines
Interviews
Neoplasm Metastasis
Medical Overuse
Incidence

Keywords

  • active surveillance
  • management
  • overdiagnosis
  • overtreatment
  • papillary microcarcinoma
  • terminology

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Clinicians' Views on Management and Terminology for Papillary Thyroid Microcarcinoma : A Qualitative Study. / Nickel, Brooke; Brito Campana, Juan; Barratt, Alexandra; Jordan, Susan; Moynihan, Ray; McCaffery, Kirsten.

In: Thyroid, Vol. 27, No. 5, 01.05.2017, p. 661-671.

Research output: Contribution to journalArticle

Nickel, Brooke ; Brito Campana, Juan ; Barratt, Alexandra ; Jordan, Susan ; Moynihan, Ray ; McCaffery, Kirsten. / Clinicians' Views on Management and Terminology for Papillary Thyroid Microcarcinoma : A Qualitative Study. In: Thyroid. 2017 ; Vol. 27, No. 5. pp. 661-671.
@article{9d1679b17c394883971d6d10547ceaac,
title = "Clinicians' Views on Management and Terminology for Papillary Thyroid Microcarcinoma: A Qualitative Study",
abstract = "Background: There is growing acceptance that the increase in thyroid cancer incidence is in part a result of overdiagnosis of small low-risk papillary microcarcinomas (PMCs) with indolent clinical course. Although surgery is the cornerstone treatment for patients with PMCs, recent management guidelines are shifting toward inclusion of more conservative treatments such as active surveillance. There is little evidence on clinicians' experience in managing PMC patients and their attitudes toward treatment options, including their willingness to accept a nonsurgical option. The aim of this study was to understand how clinicians perceive a diagnosis of PMC, potential changes to terminology, and the treatment options available to patients. Methods: This was a qualitative study using semi-structured interviews conducted between November 2015 and May 2016 with 22 clinicians (seven endocrinologists and 15 thyroid surgeons). Transcribed audio-recordings were thematically coded, and a framework method was used to analyze the data. Results: Across a sample of clinicians who manage thyroid cancer patients, awareness of overdiagnosis and overtreatment of PMC was common. However, there was little acceptance of active surveillance to manage these patients. Clinicians did not feel comfortable recommending this management approach, as they were worried about the risk of metastases, did not feel that evidence to support this approach was strong enough, and also believed that patients currently have a high preference for surgery. The majority of clinicians did not believe that changing the terminology of this diagnosis was a viable strategy to reduce patients' anxiety and their perceived preference for more aggressive treatments. However, most clinicians felt that thyroid nodules <1 cm should not be biopsied, which could help minimize the risk of overdiagnosis of PMC. Conclusions: This study, based on a non-representative sample of 22 clinicians, which remains an important limitation, provides revealing insight into clinicians' management preferences and decision making for small low-risk thyroid cancers at a time when management guidelines and practices are evolving. It suggests that clinicians may not be ready to accept nonsurgical options, or changes in terminology, until evidence to support these options and changes is stronger.",
keywords = "active surveillance, management, overdiagnosis, overtreatment, papillary microcarcinoma, terminology",
author = "Brooke Nickel and {Brito Campana}, Juan and Alexandra Barratt and Susan Jordan and Ray Moynihan and Kirsten McCaffery",
year = "2017",
month = "5",
day = "1",
doi = "10.1089/thy.2016.0483",
language = "English (US)",
volume = "27",
pages = "661--671",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Clinicians' Views on Management and Terminology for Papillary Thyroid Microcarcinoma

T2 - A Qualitative Study

AU - Nickel, Brooke

AU - Brito Campana, Juan

AU - Barratt, Alexandra

AU - Jordan, Susan

AU - Moynihan, Ray

AU - McCaffery, Kirsten

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: There is growing acceptance that the increase in thyroid cancer incidence is in part a result of overdiagnosis of small low-risk papillary microcarcinomas (PMCs) with indolent clinical course. Although surgery is the cornerstone treatment for patients with PMCs, recent management guidelines are shifting toward inclusion of more conservative treatments such as active surveillance. There is little evidence on clinicians' experience in managing PMC patients and their attitudes toward treatment options, including their willingness to accept a nonsurgical option. The aim of this study was to understand how clinicians perceive a diagnosis of PMC, potential changes to terminology, and the treatment options available to patients. Methods: This was a qualitative study using semi-structured interviews conducted between November 2015 and May 2016 with 22 clinicians (seven endocrinologists and 15 thyroid surgeons). Transcribed audio-recordings were thematically coded, and a framework method was used to analyze the data. Results: Across a sample of clinicians who manage thyroid cancer patients, awareness of overdiagnosis and overtreatment of PMC was common. However, there was little acceptance of active surveillance to manage these patients. Clinicians did not feel comfortable recommending this management approach, as they were worried about the risk of metastases, did not feel that evidence to support this approach was strong enough, and also believed that patients currently have a high preference for surgery. The majority of clinicians did not believe that changing the terminology of this diagnosis was a viable strategy to reduce patients' anxiety and their perceived preference for more aggressive treatments. However, most clinicians felt that thyroid nodules <1 cm should not be biopsied, which could help minimize the risk of overdiagnosis of PMC. Conclusions: This study, based on a non-representative sample of 22 clinicians, which remains an important limitation, provides revealing insight into clinicians' management preferences and decision making for small low-risk thyroid cancers at a time when management guidelines and practices are evolving. It suggests that clinicians may not be ready to accept nonsurgical options, or changes in terminology, until evidence to support these options and changes is stronger.

AB - Background: There is growing acceptance that the increase in thyroid cancer incidence is in part a result of overdiagnosis of small low-risk papillary microcarcinomas (PMCs) with indolent clinical course. Although surgery is the cornerstone treatment for patients with PMCs, recent management guidelines are shifting toward inclusion of more conservative treatments such as active surveillance. There is little evidence on clinicians' experience in managing PMC patients and their attitudes toward treatment options, including their willingness to accept a nonsurgical option. The aim of this study was to understand how clinicians perceive a diagnosis of PMC, potential changes to terminology, and the treatment options available to patients. Methods: This was a qualitative study using semi-structured interviews conducted between November 2015 and May 2016 with 22 clinicians (seven endocrinologists and 15 thyroid surgeons). Transcribed audio-recordings were thematically coded, and a framework method was used to analyze the data. Results: Across a sample of clinicians who manage thyroid cancer patients, awareness of overdiagnosis and overtreatment of PMC was common. However, there was little acceptance of active surveillance to manage these patients. Clinicians did not feel comfortable recommending this management approach, as they were worried about the risk of metastases, did not feel that evidence to support this approach was strong enough, and also believed that patients currently have a high preference for surgery. The majority of clinicians did not believe that changing the terminology of this diagnosis was a viable strategy to reduce patients' anxiety and their perceived preference for more aggressive treatments. However, most clinicians felt that thyroid nodules <1 cm should not be biopsied, which could help minimize the risk of overdiagnosis of PMC. Conclusions: This study, based on a non-representative sample of 22 clinicians, which remains an important limitation, provides revealing insight into clinicians' management preferences and decision making for small low-risk thyroid cancers at a time when management guidelines and practices are evolving. It suggests that clinicians may not be ready to accept nonsurgical options, or changes in terminology, until evidence to support these options and changes is stronger.

KW - active surveillance

KW - management

KW - overdiagnosis

KW - overtreatment

KW - papillary microcarcinoma

KW - terminology

UR - http://www.scopus.com/inward/record.url?scp=85018279613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018279613&partnerID=8YFLogxK

U2 - 10.1089/thy.2016.0483

DO - 10.1089/thy.2016.0483

M3 - Article

C2 - 28322617

AN - SCOPUS:85018279613

VL - 27

SP - 661

EP - 671

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 5

ER -